Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies

IOVANCE BIOTHERAPEUTICS, INC.

Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.
Jefferies will receive 3.0% commission on gross proceeds from any shares sold.
Sales may be made from time to time at the Company's discretion; no obligation to sell.
Prospectus supplement dated August 22, 2025, filed under existing S-3ASR registration statement.
Agreement is an amendment and restatement of prior open market sale agreement.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.